Felbamate for infantile spasms syndrome resistant to first-line treatments.
Dev Med Child Neurol
; 62(5): 581-586, 2020 05.
Article
em En
| MEDLINE
| ID: mdl-31850517
ABSTRACT
AIM:
To analyse the effects of felbamate in refractory infantile spasms/West syndrome.METHOD:
We conducted a 10-year retrospective study of infants (including all infants younger than 18mo) treated with felbamate for electroencephalography-recorded epileptic spasms persisting after first-line treatment.RESULTS:
In total, 29 infants (17 males, 12 females) were included in the study. Felbamate was initiated at a mean age of 13.8 months (range 4.5-66mo) after sequential administration or combination of vigabatrin and oral steroids; a ketogenic diet was implemented in 23 infants. Eight infants became spasm-free at a mean dose of 34.6mg/kg/day felbamate (range 26-45mg/kg/day). Mean duration of felbamate use was 19 months (range 1-67mo) for the 19 infants whose treatment was terminated. No severe side effects were observed. Reversible neutropenia led to withdrawal of felbamate in six patients. One spasm-free patient demonstrated recurrence when felbamate was withdrawn.INTERPRETATION:
N-methyl-d-aspartate receptors with felbamate controlled epileptic spasms in eight infants resistant to first-line treatment should be targeted.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Espasmos Infantis
/
Felbamato
/
Anticonvulsivantes
Tipo de estudo:
Observational_studies
Limite:
Female
/
Humans
/
Infant
/
Male
Idioma:
En
Revista:
Dev Med Child Neurol
Ano de publicação:
2020
Tipo de documento:
Article
País de afiliação:
França